ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Ascendis Pharma A/S

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 11, 2026

$229.95+4.70 (+2.09%)

Close on Oct 19, 2026

Ascendis Pharma A/S balance sheet

Annual Quarterly

EUR USD

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Cash & Equivalents	723	579	434	476	505	715	671	318	235	190	130	61
Cash & Short-Term Investments	723	579	434	476	505	715	671	318	235	190	130	61
Receivables	166	172	40	13	2.49	0.47	0.90	0.01	0.23	0.30	–	–
Inventory	354	306	231	140	85	0	–	–	–	–	–	–
Total Current Assets	1,302	1,098	777	988	912	905	686	336	246	194	–	–
Property, Plant & Equipment	172	102	122	138	143	132	51	4.95	3.07	2.48	–	–
Operating Lease Right-of-Use Assets	36	12	14	–	–	–	–	21	–	–	–	–
Goodwill	–	–	–	–	–	–	3.92	4.00	4.20	3.69	–	–
Total Assets	1,529	1,221	913	1,166	1,228	1,198	760	365	254	201	–	–
Accounts Payable	–	–	–	–	–	–	–	–	29	14	–	–
Short-Term Debt	504	474	450	427	7.92	–	–	–	–	–	–	–
Current Debt	504	474	450	427	7.92	–	–	–	–	–	–	–
Current Portion of Leases	–	–	16	15	7.92	8.39	6.62	–	–	–	–	–
Other Current Liabilities	68	70	46	34	34	29	15	–	–	–	–	–
Total Current Liabilities	1,255	940	815	767	114	65	54	45	29	14	–	–
Long-Term Debt	452	378	247	102	111	–	–	–	–	–	–	–
Long-Term Leases	–	–	94	102	111	104	34	–	–	–	–	–
Operating Lease Liabilities	178	96	109	117	119	112	41	20	–	–	–	–
Deferred Tax Liabilities	11	7.51	6.45	0	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	0	3.87	1.02	–	–	–	–	–
Total Liabilities	1,720	1,330	1,074	884	228	173	89	45	29	14	–	–
Total Debt	956	852	697	529	119	–	–	–	–	–	–	–
Common Stock	9.77	8.44	8.57	8.21	8.65	8.83	7.23	6.48	5.97	4.59	–	–
Treasury Stock	-0.09	-0.12	-0.16	-0.16	-0.02	0	–	–	–	–	–	–
Total Equity	-191	-109	-161	282	1,000	1,026	670	321	225	186	131	55
Total Liabilities & Equity	1,529	1,221	913	1,166	1,228	1,198	760	365	254	201	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 91.3%
Operating margin: 25.4%
Net margin: 70.8%
Return on equity, FY2025: –

Financial strength

Current ratio: 2.99
Debt to equity: –
Debt to assets: 16.8%
Cash to current liabilities: 174.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.